Evidence map›Paper›PMID 42606789›Full record

ArticleImmunologic research2026

Comparative analysis of multiple sclerosis burden in China and India from 1990 to 2021 based on the Global Burden of Disease Study 2021.

Zhuo-Lei Cai, Fei Dong, Jinyu Ma, Dujun Wang, Wenmin Yi, Lei Cao, Zhi-You Cai

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in Immunologic research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Zhuo-Lei Cai *Department of Neurology, The Second Affiliated Hospital of Anhui Medical University, No. 678 Furong Road, Hefei, Anhui, China.
Fei Dong *Department of Neurology, The First Affiliated Hospital of Zhengzhou University, No. 1 Jianshe East Road, Zhengzhou, Henan, China.
Jinyu Ma *Clinical College of Anhui Medical University, No. 1166, Wangjiangxi Road, Shushan District, Hefei City, Anhui Province, P.R. China.
Dujun WangLiangjiang New Area People's Hospital, Chongqing Medical University, No. 2, Jinkai Avenue, Liangjiang New Area, Chongqing, China.
Wenmin YiLiangjiang New Area People's Hospital, Chongqing Medical University, No. 2, Jinkai Avenue, Liangjiang New Area, Chongqing, China.
Lei CaoDepartment of Neurology, The Second Affiliated Hospital of Anhui Medical University, No. 678 Furong Road, Hefei, Anhui, China. caolei0531@163.com.
Zhi-You CaiLiangjiang New Area People's Hospital, Chongqing Medical University, No. 2, Jinkai Avenue, Liangjiang New Area, Chongqing, China. caizhiyou@ucas.ac.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system and one of the leading causes of non-traumatic neurological disability among young adults worldwide. In recent years, an increasing number of cases have been reported in traditionally low-risk regions, including parts of Asia such as China and India. Our study aims to systematically compare the disease burden and long-term trends of MS in China and India from 1990 to 2021, and provide evidence for public health strategies in both countries. Data were obtained from the Global Burden of Disease Study 2021. Metrics including incidence, prevalence, mortality, and disability-adjusted life years (DALYs) related to MS in China and India were extracted. We calculated age-standardized rates for comparative analysis. Estimated annual percentage change (EAPC) and Joinpoint regression were used to assess trends. An age-period-cohort (APC) model was applied to disentangle the effects of age, period, and birth cohort. Bayesian APC modeling was used to project disease burden until 2040. India consistently demonstrated higher rates of incidence, prevalence, mortality, and DALYs than China. Joinpoint regression revealed a significant increase in DALYs in China between 2018 and 2021, whereas India exhibited a sustained upward trend over the study period. Decomposition analysis indicated that population growth was the primary driver of increased MS burden in both countries, with epidemiological changes playing an additional notable role in China. Projections suggested that prevalence in China will continue to rise due to extended patient survival, while most indicators in India are expected to decline. APC analysis identified clear age and period effects in both countries. Overall, both China and India face an increasingly heavy disease burden. In terms of age distribution, the disease burden in both countries is primarily concentrated among young- and middle-aged adults, and women are more affected. However, significant differences exist between the two nations in specific indicators and their underlying drivers. Projections indicate that all indicators in India show a downward trend. Although China exhibited an overall downward trajectory, certain sub-indicators are rising. It is potentially linked to improvements in China's diagnostic and treatment capabilities.

Indexed as

Multiple SclerosisAdolescentAdultChinaDisability-Adjusted Life YearsFemaleGlobal Burden of DiseaseHumansIncidenceIndiaMaleMiddle AgedPrevalenceYoung AdultAPCChinaComparative analysisDecomposition analysisDemyelinating diseasesDisease burdenForecast AnalysisGBDIndiaMultiple sclerosis

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.